Where does TVRD stock trade?

Tvardi Therapeutics Inc. (TVRD) is listed on NASDAQ.

What sector and industry is TVRD in?

Tvardi Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

When did Tvardi Therapeutics Inc. go public?

Tvardi Therapeutics Inc. (TVRD) completed its IPO in 2014.

What are analysts saying about TVRD?

Tvardi Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $900.00 price target on 2026-06-08. Recent price targets range from $300.00 to $900.00.

What companies are similar to TVRD?

Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TVRD side-by-side with any of them on Quantisnow.

How can I track TVRD on Quantisnow?

Quantisnow aggregates Tvardi Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TVRD to receive live email and push alerts on every new disclosure.

TVRD

NASDAQ

Tvardi Therapeutics Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2014

$2.66-0.02 (-0.75%)

News25/Ratings12

Price$2.66-0.05 (-1.85%)

02:45 PM04:00 PM

News · 26 weeks33-80%

2025-12-142026-06-07

Mix1890d

SEC Filings12(67%)
Other4(22%)
Analyst2(11%)

Latest news

25 items

3dANALYST
H.C. Wainwright initiated coverage on Tvardi Therapeutics with a new price target
H.C. Wainwright initiated coverage of Tvardi Therapeutics with a rating of Buy and set a new price target of $9.00
21dPR
Tvardi Therapeutics to Participate in Upcoming Investor Events
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in the following upcoming investor events: Jefferies Global Healthcare ConferenceFormat: Fireside Chat and 1-on-1 MeetingsDate: Thursday, June 4, 2026Time: 8:10 AM ETLocation: New York, NY Raymond James BioPharma CEO Strategy SeriesFormat: Fireside ChatDate: Friday, June 5, 2026Time: 10:00 AM ETRegistration Link: Here The webcasts of the Jefferies and Raymond James firesid
28dSEC
SEC Form EFFECT filed by Tvardi Therapeutics Inc.
EFFECT - Tvardi Therapeutics, Inc. (0001346830) (Filer)
29dSEC
SEC Form EFFECT filed by Tvardi Therapeutics Inc.
EFFECT - Tvardi Therapeutics, Inc. (0001346830) (Filer)
33dSEC
SEC Form POS AM filed by Tvardi Therapeutics Inc.
POS AM - Tvardi Therapeutics, Inc. (0001346830) (Filer)
34dSEC
SEC Form 10-Q filed by Tvardi Therapeutics Inc.
10-Q - Tvardi Therapeutics, Inc. (0001346830) (Filer)
34dSEC
Tvardi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
34dPR
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) on track for 2H 2026 Cash runway expected to be sufficient to fund operations through clinical readouts and into Q4 2026 HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its ﬁnancial and operating results for the first quarter ended Mar
40dSEC
SEC Form S-3 filed by Tvardi Therapeutics Inc.
S-3 - Tvardi Therapeutics, Inc. (0001346830) (Filer)
48dSEC
SEC Form DEFA14A filed by Tvardi Therapeutics Inc.
DEFA14A - Tvardi Therapeutics, Inc. (0001346830) (Filer)
48dSEC
SEC Form DEF 14A filed by Tvardi Therapeutics Inc.
DEF 14A - Tvardi Therapeutics, Inc. (0001346830) (Filer)
52dANALYST
Tvardi Therapeutics downgraded by Barclays with a new price target
Barclays downgraded Tvardi Therapeutics from Equal Weight to Underweight and set a new price target of $3.00
71dSEC
SEC Form S-8 filed by Tvardi Therapeutics Inc.
S-8 - Tvardi Therapeutics, Inc. (0001346830) (Filer)
71dSEC
SEC Form POS EX filed by Tvardi Therapeutics Inc.
POS EX - Tvardi Therapeutics, Inc. (0001346830) (Filer)
71dSEC
SEC Form 424B3 filed by Tvardi Therapeutics Inc.
424B3 - Tvardi Therapeutics, Inc. (0001346830) (Filer)
71dSEC
SEC Form 10-K filed by Tvardi Therapeutics Inc.
10-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
71dSEC
Tvardi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
71dPR
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 2026 Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) are anticipated in H2 2026 Cash runway expected to be sufficient to fund operations into Q4 2026 after clinical readouts HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced its ﬁnancial and operating results for the fourth quarter and full-year ended December 31, 2025, and prov
96dSEC
SEC Form 424B3 filed by Tvardi Therapeutics Inc.
424B3 - Tvardi Therapeutics, Inc. (0001346830) (Filer)
96dSEC
Tvardi Therapeutics Inc. filed SEC Form 8-K: Other Events
8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
119dPR
Tvardi Therapeutics to Participate in Upcoming Investor Conferences
HOUSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that management will participate in the following upcoming investor conferences: JonesTrading C-Suite Fireside Chat SeriesDate: Wednesday, February 19, 2026Time: 11:00 AM ESTRegistration Link here Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFormat: Corporate presentationDate: Wednesday, February 25, 2026Time: 10:40 AM ESTLocation: Virtual TD Cowen 46th Annual Health Care ConferenceFormat: Corporate prese
128dINSIDER
SEC Form 4 filed by Chief Financial Officer Conn Avi Daniel
4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
128dINSIDER
SEC Form 4 filed by Principal Accounting Officer O'Brien Stephen Paul
4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
128dINSIDER
SEC Form 4 filed by Chief Medical Officer Kauh John Saewook M.D.
4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
128dINSIDER
SEC Form 4 filed by Chief Executive Officer Alibhai Imran Nizamudin
4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

Analyst ratings

Last 12

Jun 8H.C. Wainwright•Update
Buy$9.00▲ 238%
Apr 20Barclays•Update
Underweight$3.00▲ 12.8%
Oct 14Barclays•Update
Equal Weight$5.00▲ 88.0%
Oct 14Raymond James•Update
Mkt Perform--
Oct 13Cantor Fitzgerald•Update
Neutral--
Oct 13Piper Sandler•Update
Neutral$4.00$78.00▲ 50.4%
Oct 13Barclays•Update
Overweight$61.00▲ 2193%
Jul 14Raymond James•Update
Outperform$62.00▲ 2231%
Jul 11Cantor Fitzgerald•Update
Overweight$52.00▲ 1855%
Jun 12Piper Sandler•Update
Overweight$78.00▲ 2832%
May 21Oppenheimer•Update
Outperform$65.00▲ 2344%
May 15BTIG Research•Update
Buy$55.00▲ 1968%

Short volume

33d, FINRA Reg SHO

58.4%Jun 10

33d avg 49.7%+8.8pp

Apr 24Short / total volumeJun 10

Short19.3KTotal33.0K

Options

4 expirations

Jun 18, 20266d

4 exp · 28

Callsstrike · last · iv · Δ

2.501.20--
5.000.15--
7.500.10--
10.00---

Putsstrike · last · iv · Δ

2.50---
5.002.82--
7.50---
10.00---

Peers

Quick links

TVRD FAQ

6 questions

Where does TVRD stock trade?
Tvardi Therapeutics Inc. (TVRD) is listed on NASDAQ.
What sector and industry is TVRD in?
Tvardi Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
When did Tvardi Therapeutics Inc. go public?
Tvardi Therapeutics Inc. (TVRD) completed its IPO in 2014.
What are analysts saying about TVRD?
Tvardi Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $900.00 price target on 2026-06-08. Recent price targets range from $300.00 to $900.00.
What companies are similar to TVRD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TVRD side-by-side with any of them on Quantisnow.
How can I track TVRD on Quantisnow?
Quantisnow aggregates Tvardi Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TVRD to receive live email and push alerts on every new disclosure.